Alnylam Pharmaceuticals, Inc. announced it has expanded the Alnylam Act™ program to include no-charge, third-party genetic testing and counseling for individuals who may carry a gene mutation known to be associated with acute hepatic porphyrias (AHPs), a family of ultra-rare, often misdiagnosed genetic diseases. AHPs are characterized by acute, potentially life-threatening abdominal attacks and chronic debilitating multi-system symptoms that severely impact patients’ quality of life. Genetic testing available through Alnylam Act is provided by Invitae, an independent, third-party genetic testing company. The genetic testing must be ordered by a healthcare professional and is available in the United States and Canada. Genetic counseling is provided by InformedDNA, an independent, third-party genetic counseling provider and is available in the U.S. only.